Clinical and Patient Reported Outcomes for Individuals With Relapsed/Refractory Multiple Myeloma Treated With Isatuximab: Real-World Insights From Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 11 Dec 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 11 Dec 2024 Planned primary completion date changed from 31 Oct 2024 to 31 Aug 2025.
- 23 May 2024 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.